| DIRECT COMPETITOR COMPARISON | |
| AVGN | KG | NVS | PFE | Industry | | Market Cap: | 42.96M | 3.00B | 126.85B | 150.01B | 129.32M | | Employees: | 12 | 3,381 | 99,000 | 81,800 | 181 | | Qtrly Rev Growth (yoy): | N/A | 19.30% | 2.40% | -2.90% | 14.60% | | Revenue (ttm): | 7.20M | 1.69B | 42.31B | 45.82B | 31.21M | | Gross Margin (ttm): | 100.00% | 68.58% | 72.61% | 86.61% | 72.39% | | EBITDA (ttm): | -7.83M | 533.79M | 11.24B | 21.31B | -1.66M | | Oper Margins (ttm): | -114.72% | 21.23% | 21.50% | 37.42% | 2.37% | | Net Income (ttm): | -10.91M | -472.15M | 7.59B | 8.09B | N/A | | EPS (ttm): | -0.366 | -1.933 | 3.34 | 1.204 | N/A | | P/E (ttm): | N/A | N/A | 16.72 | 15.44 | 13.80 | | PEG (5 yr expected): | N/A | 1.6 | 2.83 | 5.9 | 2.09 | | P/S (ttm): | 6.30 | 1.78 | 2.97 | 3.22 | 3.27 |
|
| KG = King Pharmaceuticals Inc. | | NVS = Novartis AG | | PFE = Pfizer Inc. | | Industry = Drug Manufacturers - Major | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.48 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | AP IMPACT: A stream of WH health care visits
Wed 5:16pm -
AP | | • | NVS | | [$$] Charting the Market Wednesday
Wed 4:57pm -
at Barrons.com | | • | PFE | | Sitting Atop An Earnings Powder Keg
Wed 4:10pm -
at Forbes.com | | • | PFE | | CORRECTED - US sees rise in secondary infections after flu
Wed 4:09pm -
at Reuters | | • | NVS | | TradingMarkets 7 Stocks You Need to Know for Friday
Wed 4:09pm -
TradingMarkets.com | | • | NVS | | Incyte Shares Up on Novartis Licensing Deal
Wed 3:53pm -
at Fox Business | | • | NVS | | Dream Stocks for Biotech Investors
Wed 3:27pm -
at Motley Fool | | • | NVS | | Prospecting for Stocks: Novartis
Wed 3:03pm -
at Motley Fool | | • | PFE | | Still Enjoying Those Acquisitions, Pfizer?
Wed 2:55pm -
at Motley Fool | | • | KG | | Monday Options Recap
Mon, Nov 23 -
at Seeking Alpha | | • | KG | | Which Drug Companies Could Be Private-Equity Targets?
Mon, Nov 23 -
at The Wall Street Journal Online | | • | KG | | King, Donaldson Lead High-Flying Stocks
Fri, Nov 20 -
at TheStreet.com | | • | KG | | 'Fast Money' Recap: Playing Defense
Thu, Nov 19 -
at TheStreet.com | | • | KG | | Market Winners & Losers: King Pharmaceuticals, MBIA
Thu, Nov 19 -
at Fox Business | | • | KG | | Your First Move For Friday November 20th
Thu, Nov 19 -
at CNBC | | • | KG | | [video] Defense, Defense
Thu, Nov 19 -
at CNBC | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
0.08 (5.26%) 
Competitors
